Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 16, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

Company ends Q2 ’21 with cash and cash equivalents of $212.2 millionRecent appointments to Company leadership strongly position Ovid to advance current and future neuroscience programsOvid is actively...
July 08, 2021 16:30 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

Dr. Michael Poole to Join the Board of Directors Dr. Claude Nicaise Appointed Head of R&D and Jason Tardio Appointed Chief Operating Officer Dr. Amit Rakhit to Join the Scientific and Clinical...
July 07, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
June 04, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
May 26, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board

New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to...
May 13, 2021 16:05 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Closed royalty, license and termination agreement with Takeda for soticlestat; Ovid Therapeutics received an upfront payment of $196.0 million and is eligible to receive up to $660.0 million in...
May 12, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
April 20, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board

NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
April 19, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

OVID Provides Update on OV101 Program and the Prioritization of its Resources

Completed Soticlestat Agreement with Takeda Provides Significant Resources to Advance and Enrich OVID’s Pipeline, Including OV882 for Angelman Syndrome Company Reiterates Anticipated Quarterly...
March 30, 2021 08:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat

NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with...